Holen Sie sich die Stockscreener-App
9.49
3.49%
0.32
Handel nachbörslich:
9.45
-0.04
-0.42%
Xilio Therapeutics Inc Aktie (XLO) Neueste Nachrichten
Weekly Recap: Xilio (XLO) Q2 revenue jump and FDA IND cleared for XTX501 - TradingView
StemPoint group (XLO) discloses 9.5% Xilio Therapeutics stake via warrants - Stock Titan
Xilio Therapeutics earnings beat by $0.25, revenue topped estimates - Investing.com Canada
Xilio Therapeutics (NASDAQ:XLO) Announces Earnings Results, Beats Estimates By $0.26 EPS - MarketBeat
Xilio Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Xilio Therapeutics Q2 Results: Sales up 131% YoY to $18.7M - scanx.trade
Xilio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Xilio Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Xilio Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Xilio Therapeutics, Inc. 2Q 2026: Revenue $18.7M, EPS $(0.33) — 10-Q Summary - TradingView
Xilio Therapeutics reports Q2 2026: $18.7M collaboration revenue, $6.4M net loss, cash $136.0M - TradingView
Xilio Therapeutics (XLO) lifts collaboration revenue and trims net loss in 2026 - Stock Titan
Xilio Therapeutics Reports $18.7 Million Q2 Revenue and FDA Clearance for XTX501 - Quiver Quantitative
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates - The Manila Times
Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates - TradingView
Xilio expects to dose cancer patients with XTX501 in H2 2026 - Stock Titan
Xilio Therapeutics (XLO) Holds Steady at $9.18 as Biotech Stock Consolidates Near SupportMomentum Factor - dars.gov.et
Xilio Therapeutics Inc (XLO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xilio Therapeutics (XLO) Expected to Announce Earnings on Thursday - MarketBeat
XLO Q2'26 Earnings: revenue estimate is 12.72M USD - TradingView
Xilio Therapeutics (NASDAQ:XLO) Trading Down 0.2%Here's Why - MarketBeat
XLO|Xilio Therapeutics Inc|Price:9.110|Chg%:+0.030 - TradingKey
Xilio Therapeutics Inc (XLO) Cash Flow - TradingKey
Xilio Therapeutics Inc (XLO) Balance Sheet - TradingKey
Xilio Therapeutics Inc (XLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xilio Therapeutics Inc (XLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xilio Therapeutics (XLO) Surges 5%: Key Levels to Watch After Breakout MoveRatio Spread Trade - dars.gov.et
Xilio Therapeutics Inc (XLO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Xilio Therapeutics Inc (XLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xilio Therapeutics Inc (XLO) Income Statement - TradingKey
XLO|Xilio Therapeutics Inc|Price:9.132|Chg%:+0.482 - TradingKey
Xilio Therapeutics, Inc. Revenue Breakdown – NASDAQ:XLO - TradingView
Xilio Therapeutics, Inc. (XLO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Price to earnings forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Xilio Therapeutics (XLO) Holds Near Support After Modest DeclineRTH Profile - dars.gov.et
Xilio Therapeutics (XLO) Holds Steady Near Resistance – Biotech Stock in Tight RangeInsider Selling Alerts - dars.gov.et
XLO Stock Price, Quote & Chart - ChartMill
Xilio Therapeutics (XLO) Slides 2% as Biotech Stock Tests Key Support LevelsVolume Rate Change - dars.gov.et
Enterprise value to EBIT forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xilio lures three new employees with 107,060 stock options - Stock Titan
Xilio Therapeutics (XLO) Slides as Biotech Sector Headwinds PersistVolume Profile - dars.gov.et
Price to sales forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell Microcap Value Benchmark Index - marketscreener.com
Enterprise value to EBITDA forward of Xilio Therapeutics, Inc. – BOATS:XLO - TradingView
Xilio Therapeutics appoints Ben Harshbarger as chief legal officer By Investing.com - Investing.com Nigeria
Xilio Therapeutics, Inc. Announces Appointment of Ben Harshbarger as Chief Legal Officer - marketscreener.com
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer - citybiz
Xilio Therapeutics appoints Ben Harshbarger as chief legal officer - Investing.com
Xilio Therapeutics taps biotech veteran Ben Harshbarger as legal chief - Stock Titan
XLO Q1 2026 Earnings: Narrower-Than-Expected Loss Fuels Optimism Amid Pipeline ProgressEPS Estimate Trend - dars.gov.et
Xilio Therapeutics, Inc.(NasdaqCM: XLO) added to Russell Microcap Index - marketscreener.com
Enterprise value to revenue forward of Xilio Therapeutics, Inc. – BOATS:XLO - TradingView
Xilio Therapeutics, Inc.(NasdaqCM: XLO) added to Russell 3000E Value Benchmark - marketscreener.com
XLO Forecast — Price Target — Prediction for 2027 - TradingView
Xilio Therapeutics Inc Actuals & Estimates (NASDAQ:XLO) - TradingView
Xilio Therapeutics Inc (XLO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XLO Price Today: Xilio Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):